Chronic hepatitis B infection associated with twice the risk of liver-related death compared to hepatitis C
Incidence of hepatitis C re-infection and clearance may be understimated
Abbott interferon-free HCV combinations show early promise in untreated patients
Boceprevir a useful option for patients who did not respond to earlier course of hepatitis C therapy
Adding TMC435 boosts response for difficult-to-treat hepatitis C patients
Hepatitis C drug alisporivir is effective, but pancreatitis a concern
Telaprevir and boceprevir show high rate of serious side-effects in hepatitis C patients with urgent need of treatment
Hepatitis C meds GS-7977, daclatasvir and asunaprevir look good in interferon-free combos
